Results 251 to 260 of about 812,191 (301)

Combined blinatumomab and CD19 CAR T-cell therapy for newly diagnosed adult Ph⁻ BCP-ALL: A retrospective study. [PDF]

Ann Hematol
Jiang B, Zhu Y, Jiang Y, Huang J, Liu Y, Tang M, Lu J, Chen S.   +7 more
europepmc   +1 more source

Light sheet microscopy imaging dataset of CAR-T-cell-mediated cytotoxicity. [PDF]

Sci Data
Wang J, Jin J, Fang Y, Chen L, Fei P.
europepmc   +1 more source

Editorial: Achilles heel of CAR T-cell therapy. [PDF]

Front Immunol
Chiriva-Internati M, Grizzi F.
europepmc   +1 more source

Involvement of the hospital pharmacist in securing the chimeric antigen receptor (CAR)-T cell circuit. [PDF]

Eur J Hosp Pharm
Bryla A, Lorent S, Vervacke A, Scolas G, Alexandre L.   +4 more
europepmc   +1 more source

Boosting CAR T-cell efficacy by blocking proteasomal degradation of membrane antigens.

Blood
Rieger L, Irlinger K, Füchsl F, Tietje M, Purcarea A, Barbian N, Faber M, Vogelsang C, Pfeuffer L, Stotz S, Karpiuk O, Schulze T, Augsburger A, Glaisner N, Konetzki V, Friedel S, Besse A, Besse L, Driessen C, Buchner M, Schwamborn K, Steiger K, Giansanti P, Theurich S, Waldschmidt J, Kortüm KM, Hudecek M, Einsele H, Högner M, Kuster B, Krackhardt AM, Hecker JS, Bassermann F.   +32 more
europepmc   +1 more source

Atypical hyperlymphocytosis following CAR T-cell infusion.

Blood
Vossen CJ, Collie AMB.
europepmc   +1 more source

Hypoxia-regulatable CAR T cells

Molecular Therapy
openaire   +2 more sources

An NK-like CAR T cell transition in CAR T cell dysfunction

Cell, 2021
Chimeric antigen receptor (CAR) T cell therapy has achieved remarkable success in hematological malignancies but remains ineffective in solid tumors, due in part to CAR T cell exhaustion in the solid tumor microenvironment. To study dysfunction of mesothelin-redirected CAR T cells in pancreatic cancer, we establish a robust model of continuous antigen ...
M Angela Aznar, Sangya Agarwal, Nils Wellhausen   +2 more
exaly   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

CAR T Cells

Neurosurgery Clinics of North America, 2021
Chimeric antigen receptor T (CAR-T) cells, an immunotherapy that demonstrates marked success in treatment of hematologic malignancies, are an emergent therapeutic for patients with glioblastoma (GBM). GBM CAR-T trials have focused on targeting well-characterized antigens in the pathogenesis of GBM.
Thilan, Tudor, Zev A, Binder, Donald M, O'Rourke   +2 more
openaire   +2 more sources